Unlocking the Potential of Nano and Micro-medicines
Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers
E. de Pablo, P. O'Connell, R. Fernández-García, S. Marchand, A. Chauzy, F. Tewes, M.A. Dea-Ayuela, D. Kumar, F. Bolás, M.P. Ballesteros, J.J. Torrado, A.M. Healy, D.R. Serrano. International Journal of Pharmaceutics, 2023.
Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses
Raquel Fernández-García, David Walsh, Peter O'Connell, Karla Slowing, Rafaela Raposo, M Paloma Ballesteros, Aurora Jiménez-Cebrián, Manuel J Chamorro-Sancho, Francisco Bolás-Fernández, Anne Marie Healy, Dolores R Serrano. European Journal of Pharmaceutics and Biopharmaceutics. 2023.
Microfluidic Manufacture of Lipid-Based Nanomedicines
Karim Osouli-Bostanabad, Sara Puliga, Dolores R Serrano, Andrea Bucchi, Gavin Halbert, Aikaterini Lalatsa. Pharmaceutics. 2022.
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
Miriam Rolon, Eustine Hanna, Celeste Vega, Cathia Coronel, Maria Auxiliadora Dea-Ayuela, Dolores R Serrano, Aikaterini Lalatsa. Pharmaceutics, 2022.
Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers
Raquel Fernández-García, Juan C. Muñoz-García, Matthew Wallace, Laszlo Fabian, Elena González-Burgos, M. Pilar Gómez-Serranillos, Rafaela Raposo, Francisco Bolás-Fernández, M. Paloma Ballesteros, Anne Marie Healy, Yaroslav Z. Khimyak, Dolores R. Serrano.Journal Controlled Release, 2022.
Mimicking bone microenvironment: 2D and 3D in vitro models of human osteoblasts
Ivan Yuste, Francis C. Luciano, Elena González, Aikaterini Lalatsa, Dolores R. Serrano. Pharmacological Research, 2021.
Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?
Alejandro Romero, Eva Ramos, Francisco López-Muñoz, Cristóbal De Los Ríos, Javier Egea, Emilio Gil-Martín, René Pita, Juan J. Torrado, Dolores R. Serrano and Antonio Juberias. Diseases, 2021
Nanoemulsified butenafine for enhanced perfromance against experimental cutanoues leishmaniasis.
Adriana Bezerra-Souza, Jéssica A. de Jesus, Márcia D. Laurenti, Aikaterini Lalatsa, Dolores R. Serrano. Lopez, Luiz Felipe D. Passero. Journal of Inmunology research 2020.
Nucleotides and AHCC enhances Th1 responses in vitro in Leishmania-Stimulated/Infected murine cells
María Auxiliadora Dea-Ayuela, Sergi Segarra, Dolores R. Serrano, Frnacisco Bolás-Fernández. Moelcules. 2020. 25(17), 3918.
Ultra-deformable lipid vesicles localise Amphotericin B in the dermis for the treatment of skin infectious diseases
Fernández-García R, Statts L, de Jesus JA, Dea-Ayuela MA, Bautista L, Simao R, Bolas Fernández F, Ballesteros MP, Dalastra Laurenti M, Passero LFD, Lalatsa A, Serrano DR. ACS Infect Dis. 2020
Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis
Katerina Lalatsa, Larry Statts, Jéssica A de Jesus, Olivia Adewusi, Maria Auxiliadora Dea Ayuela, Francisco Bolas-Fernandez, Marcia Dalastra Laurenti, Luiz Felipe Passero, Dolores R. Serrano. Int. J. Pharm. 2020
Editorial: Antifungal and Antiparasitic Drug Delivery - Special Issue in MDPI Pharmaceutics Journal
Juan José Torrado, Dolores R. Serrano and Javier Capilla. Pharmaceutics 2020, 12(4), 324 Pharmaceutics 2020, 12(4), 324; https://doi.org/10.3390/pharmaceutics12040324
Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis
Pablo Bilbao-Ramos, Dolores R. Serrano, Helga Karina Ruiz Saldaña, Juan J. Torrado, Francisco Bolás-Fernández and María Auxiliadora Dea-Ayuela. Pharmaceutics. 2020. doi: 4; doi: 0.3390/molecules25061394
Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale
Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Int J Pharm. 2019 Oct 31:118817. doi: 10.1016/j.ijpharm.2019.118817
Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against Aspergillosis
Pérez-Cantero A, Serrano DR, Navarro-Rodríguez P, Schätzlein AG, Uchegbu IF, Torrado JJ, Capilla J. Pharmaceutics. 2019 Sep 3;11(9). pii: E456. doi: 10.3390/pharmaceutics11090456
Designing Fast-Dissolving Orodispersible Films of Amphotericin B for Oropharyngeal Candidiasis
Serrano DR, Fernandez-Garcia R, Mele M, Healy AM, Lalatsa A. Pharmaceutics. 2019 Aug 1;11(8). pii: E369. doi: 10.3390/pharmaceutics11080369.
Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
Bezerra-Souza A, Fernandez-Garcia R, Rodrigues GF, Bolas-Fernandez F, Dalastra Laurenti M, Passero LF, Lalatsa A, Serrano DR. Pharmaceutics. 2019 Jul 20;11(7). pii: E353. doi: 10.3390/pharmaceutics11070353
Applying Loop-mediated Isothermal Amplification (LAMP) in the Diagnosis of Malaria, Leishmaniasis and Trypanosomiasis as Point-of-Care Tests (POCTs)
Dea-Ayuela MA, Galiana-Roselló C, Lalatsa A, Serrano DR. Curr Top Med Chem. 2018;18(16):1358-1374. doi: 10.2174/1568026618666181025095735
Orally Bioavailable and Effective Buparvaquone Lipid Based Nanomedicines for Visceral Leishmaniasis
Smith L, Serrano DR, Mauger M, Bolás-Fernández F, Dea-Ayuela MA, Lalatsa A. Mol Pharm. 2018 Jul 2;15(7):2570-2583. doi: 10.1021/acs.molpharmaceut.8b 00097
New aerosol formulation to control ciprofloxacin pulmonary concentration
Lamy B, Tewes F, Serrano DR, Lamarche I, Gobin P, Couet W, Healy AM, Marchand S. J Control Release. 2018 Feb 10;271:118-126. doi: 10.1016/j.jconrel. 2017.12.021.
Nebulised antibiotherapy: Conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?
de Pablo E, Fernández-García R, Ballesteros MP, Torrado JJ, Serrano DR. Ann Transl Med. 2017 Nov;5(22):448. doi: 10.21037/atm.2017.09.17
A Comparative Study on the Performance of Inert and Functionalized Spheres Coated with Solid Dispersions Made of Two Structurally Related Antifungal Drugs
Mugheirbi NA, O'Connell P, Serrano DR, Healy AM, Taylor LS, Tajber L. Mol Pharm. 2017 Nov 6;14(11):3718-3728. doi: 10.1021/acs.molpharmaceut.7b00482.
Engineering Synergistically Active and Bioavailable Cost-effective Medicines for Neglected Tropical Diseases; The Role of Excipients
Serrano DR, Lalatsa A, Dea-Ayuela MA. Curr Top Med Chem. 2017 Jul 19. doi: 10.2174/1568026617666170719164318.
Efficacy of a poly-aggregated formulation of amphotericin B in treating systemic sporotrichosis caused by Sporothrix brasiliensis
Ishida K, Castro RA, Torrado JJ, Serrano DR, Borba-Santos LP, Quintella LP, de Souza W, Rozental S, Lopes-Bezerra LM. Med Mycol. 2018 Apr 1;56(3):288-296. doi: 10.1093/mmy/myx040.
Oral amphotericin B: The journey from bench to market
Serrano DR, Lalatsa A. J Drug Deliv Sci and Tech. 2017 Dec 42: 75-83. doi:10.1016/j.jddst.2017.04.017
Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting
Fernández-García R, de Pablo E, Ballesteros MP, Serrano DR. Int J Pharm. 2017 Jun 15;525(1):139-148. doi: 10.1016/j.ijpharm.2017.04.013.
Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections
Rolón M, Serrano DR, Lalatsa A, de Pablo E, Torrado JJ, Ballesteros MP, Healy AM, Vega C, Coronel C, Bolás-Fernández F, Dea-Ayuela MA. Mol Pharm. 2017 Apr 3;14(4):1095-1106. doi: 10.1021/acs.molpharmaceut.6b01034
Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials
Serrano DR, Gallagher KH, Healy AM. Curr Top Med Chem. 2015;15(22):2327-40.
Oral Particle Uptake and Organ Targeting Drives the Activity of Amphotericin B Nanoparticles
Serrano DR, Lalatsa A, Dea-Ayuela MA, Bilbao-Ramos PE, Garrett NL, Moger J, Guarro J, Capilla J, Ballesteros MP, Schätzlein AG, Bolás F, Torrado JJ, Uchegbu IF. Mol Pharm. 2015 Feb 2;12(2):420-31. doi: 10.1021/mp500527x
Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis
Corral MJ, Serrano DR, Moreno I, Torrado JJ, Domínguez M, Alunda JM. J Antimicrob Chemother. 2014 Dec;69(12):3268-74. doi: 10.1093/jac/dku290.
New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp
Ruiz HK, Serrano DR, Dea-Ayuela MA, Bilbao-Ramos PE, Bolás-Fernández F, Torrado JJ, Molero G. Int J Pharm. 2014 Oct 1;473(1-2):148-57. doi: 10.1016/j.ijpharm.2014.07.004.
Amphotericin B Formulations – The Possibility of Generic Competition
Serrano DR, Ballesteros, MP, Schätzlein AG, Torrado JJ, Uchegbu IF. Pharmaceutical Nanotechnology 2013 1(4). doi: 10.2174/2211738501999131118125018.
Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations
Serrano DR, Hernández L, Fleire L, González-Alvarez I, Montoya A, Ballesteros MP, Dea-Ayuela MA, Miró G, Bolás-Fernández F, Torrado JJ. Int J Pharm. 2013 Apr 15;447(1-2):38-46. doi: 10.1016/j.ijpharm.2013.02.038
The oral delivery of amphotericin B
Torrado JJ, Serrano DR, Uchegbu IF. Ther Deliv. 2013 Jan;4(1):9-12. doi.org/10.4155/tde.12.134
A novel formulation of solubilised amphotericin B designed for ophthalmic use
Serrano DR, Ruiz-Saldaña HK, Molero G, Ballesteros MP, Torrado JJ. Int J Pharm. 2012 Nov 1;437(1-2):80-2. doi: 10.1016/j.ijpharm.2012.07.065
